HEALTHSTORY 544· JUNE 30, 2026

FDA's Top Gene Therapy Regulator Vijay Kumar Steps Down Amid Continuing CBER Turnover

Vijay Kumar, the acting director of the Food and Drug Administration's Office of Therapeutic Products — the unit that reviews cell and gene therapies for safety and approval — is leaving his post, according to an internal email obtained by…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 543PrimeStone Capital Presses Gresham House Energy Storage Fund Board to Launch Sale Process NEXT STORY 545 →Ping An Climbs to No. 26 on Forbes Global 2000, Ranks Second Among World's Insurers

Keep reading

More from the desk.

04HEALTH

Senate contempt vote against Anthony Fauci diverts attention from China's documented obstruction of Covid-19 data

A Senate committee voted last week to hold Anthony Fauci in contempt of Congress after he invoked the Fifth Amendment, the constitutional protection against self-incrimination, during hearin

health2 MIN

24HEALTH

FDA clears Replimune's melanoma drug Tudriqev after two rejections

A cancer treatment rejected twice by federal regulators has now won approval. The Food and Drug Administration granted accelerated approval to Tudriqev, a drug made by the biotech company Replimune, for patients with advanced melanoma…

health2 MIN

62HEALTH

Seven months after launch, Aurora Therapeutics scraps its lead gene-editing program and cuts staff

Personalized CRISPR therapies, gene-editing treatments built around one patient's specific mutation rather than a disease shared by millions, just lost one of their early backers. Aurora Therapeutics has scrapped its lead program and laid…

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk